Incyte Reports 71% Response Rate in Phase 1 Colorectal Cancer Trial
Incyte reported a 71% response rate for its INCA33890 combination in a Phase 1 colorectal cancer trial.
Related stories
Samsung Electronics shares rise 3%
M impact | EQUITY | Nov 11, 2026, 03:20 AM UTC
Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share
Mebuki Financial Raises Annual Dividend Forecast to ¥48 Per Share Mebuki Financial Group raised
L impact | EQUITY | Nov 11, 2026, 03:09 AM UTC
Mebuki Financial Group to Buy Back Up to 0.95% of Shares
Mebuki Financial Group plans a share buyback worth up to 10 billion yen.
L impact | EQUITY | Nov 11, 2026, 03:02 AM UTC
Asian session market picture: S&P 500 +0.44%, Nasdaq 100 +0.96%; USD/JPY +0.06%, WTI +0.56%, 9984 leads volume
Asian session market picture. US index futures: S and P futures is up 0.44 percent, Nasdaq futures is up 0.96 percent, Dow futures is up 0.19 percent and Russell futures is up 0.23
M impact | EQUITY | Nov 11, 2026, 03:00 AM UTC
Japan’s Nikkei rises for a third day
Japan’s Nikkei rose for a third day. The headline attributes the move to data and earnings fueling AI optimism.
M impact | EQUITY | Nov 11, 2026, 02:51 AM UTC
Inzisoft to Acquire KRW 2 Billion of Its Own Shares
M impact | EQUITY | Nov 11, 2026, 02:43 AM UTC